CD7-targeted cell therapy with stem cell transplant for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment that uses your own immune cells (CAR-T) engineered to find and attack CD7 on T-cell lymphoma cells, followed by a stem cell transplant to rebuild your immune system. It is for people with certain types of T-cell lymphoma that have come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 65 years old.
- You must have a type of T-cell lymphoma (called T-cell non-Hodgkin's lymphoma) that has CD7 on the cell surface (confirmed by a lab test).
- Your lymphoma must not have responded well to at least one round of chemotherapy, or it came back within a year after treatment.
- You need to have at least one tumor that can be measured (for example, a lymph node at least 1.5 cm across).
- You must be well enough to carry out daily activities (ECOG score 0-2) and have adequate heart, lung, liver, and kidney function.
- You cannot have had a previous stem cell or organ transplant, or have other active cancers or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
This trial tests a new cell therapy called CD7 CAR-T that targets a specific protein on your cancer cells. It is for people with T-cell lymphoma or T-cell leukemia that has not responded to other treatments or has come back.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new treatment made from your own immune cells, designed to target and kill cancer cells that have a protein called CD7. It might help people with T-cell leukemia or lymphoma that has returned or not responded to standard treatments.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.